NVS receives Breakthrough Therapy Designation (BTD) for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises in sickle cell disease Crizanlizumab is under development as a monthly … [Read more...] about MS Morning Update-1/08/2019
Market Updates
MS Monday Update-ADMA, CELG
LEAVE A COMMENT AND CLICK HERE TO SUBSCRIBE FOR MS ARTICLE ALERTS AND OUR NEWSLETTER! Adma Biologics (Nasdaq: ADMA) announced today filing of supplementary information to the FDA in … [Read more...] about MS Monday Update-ADMA, CELG
MS Morning Update
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets
Leave a comment and click here to subscribe for MS article alerts and our newsletter! Adamis Pharmaceutical (NASDAQ: ADMP), a speciality pharmaceutical company, upheld its commitment to file a new … [Read more...] about ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets
ADMP 3rd Quarter Revenue Miss and Downgrade Withstood Market Scrutiny
Admais Pharmaceuticals (Nasdaq: ADMP) was down 20% at one point yesterday after missing revenue expectations by $1.43 million and a downgrade from buy to neutral by a B.Riley/FBR analyst who slashed … [Read more...] about ADMP 3rd Quarter Revenue Miss and Downgrade Withstood Market Scrutiny
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GALT Insider selling and Form S-3/A Equal Bullish Signals-BO and Good Data Anticipated
We wanted to give GALT shareholders a quick update here on our interpretation of the recent insider selling and form S-3/A. The form 4 filed yesterday and the S-3/A filed on August 23rd are positive … [Read more...] about GALT Insider selling and Form S-3/A Equal Bullish Signals-BO and Good Data Anticipated
ADMP Up 10% Two Weeks After Recommendation
If you are following us and do not yet have a trading account we strongly encourage you to take that first, crucial step, and get one. We are constantly screening for undervalued stocks in the biotech … [Read more...] about ADMP Up 10% Two Weeks After Recommendation
GALT Upgraded By Analysts
Today on September 5th, 2018 BidAskClub upgraded Galectin Therapeutics (GALT) from a 'hold' rating to a 'buy' rating for it's investor following. Other analyst have raised their expectations … [Read more...] about GALT Upgraded By Analysts
You must be logged in to post a comment.